RESEARCH Engaging Research to Achieve Cancer Care Equity Webinar: Clinical Trials – Optimizing Diversity, Equity & Inclusivity Join panelists from the National Cancer Institute, Vanderbilt-Ingram Cancer Center, AstraZeneca, and ConcertAI to build an understanding of: obstacles that restrict patient diversity in clinical trials; how clinical researchers can strike the correct balance of scientific and ethical imperatives to ensure equitable access and outcomes in clinical research; and how sponsors, patients and investigators have overcome historical biases in clinical trials. Webinar: ERACE: Building Research and Knowledge to Eliminate Disparities In a focused discussion among pharmaceutical executives and academic researchers, we explore 1) the historical and anticipated contributors to inequities in cancer care; 2) the organizational overhaul needed to effect change; 3) and how local, state and federal regulations and incentives can move the industry forward such that we may achieve health equity for all patients. We are pleased to announce that two grant applications have been accepted for the ERACE Research Award. The grant includes access to ERACE’s Real-world data (RWD) patient registry in support of cancer disparity research. Read the latest research focused on racial differences in demographics, diagnoses and symptoms among oncology patients. Assessment of differences in demographic characteristics and clinical diagnoses among black and white oncology patients with COVID Read More Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer Read More See more ConcertAI research published at the 2021 ASCO Annual Meeting. Read More The partnerships and collaborations formed under ERACE reaffirm our commitment toward achieving cancer health equity National Cancer Institute ASCO Janssen Bristol Myers Squibb Yale University School of Medicine AmeriHealth Syneos Health The Roux Institute at Northeastern University Previous The currents of the racial justice movement and the Covid-19 pandemic have amplified persistent and pernicious disparities in access and outcomes across so many aspects of American life, including cancer care. Many people are aware of the dire — and disproportionate — consequences that Covid-19 has had on the Latinx and Black American communities. New research shows that newly diagnosed Black cancer patients are at a higher risk of severe Covid-19 than white patients. Read More Next Health Disparities in Cancer Care Minorities in the US bear a disproportionate burden of cancer compared with other population groups. The health disparities and measurable differences in outcomes manifest across the cancer care continuum, from prevention and diagnosis, through treatment, monitoring and mortality. This understanding guided ConcertAI to form ERACE (Engaging Research to Achieve Cancer Care Equity), a multidisciplinary initiative to better understand cancer disparities and create innovative solutions to eliminate them. ERACE has partnered with institutions and investigators in cancer inequities Otis W. Brawley, MD Otis Webb Brawley is an American physician and the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University. He served as Chief Medical and Scientific Officer and Executive Vice President of the American Cancer Society from 2007 to 2018. Tuya Pal, MD Tuya Pal is Associate Director of Cancer Health Disparities and Ingram Professor of Cancer Research at the Vanderbilt-Ingram Cancer Center, a practicing Clinical Geneticist focused on Inherited Cancers, and Professor of Medicine at the Vanderbilt University Medical Center. Christopher Lathan, MD, MS, MPH Chris Lathan is a Medical Director at the Dana-Farber Cancer Institute, a Faculty Director at the Cancer Care Equity Program, Pulmonary Oncologist and Assistant Professor of Medicine at Harvard Medical School. Erica Warner, ScD, MPH Dr. Warner is an Assistant Professor in the Department of Medicine at Harvard Medical School and an Assistant Investigator at MGH. She is a member of the Dana-Farber Harvard Cancer Center in the Cancer Epidemiology and Risk and Health Disparities Programs. ASCO QUALITY CARE SYMPOSIUM Racial Disparities in Performance Status A new study by ConcertAI based on patient-reported outcomes makes another compelling case for addressing disparities in treatment outcomes and racially biased access to clinical trials – and for why a new research focus is imperative. See Full Study Methods Retrospective Study of Self-Assessed Performance Status (ECOG) BACKGROUND Clinical trials lack adequate number of racial minorities. Performance status often a criterion for clinical research. Poor performance status can exclude patients from clinical trial participation. PATIENT IN STUDY 0 55.4% White 38.0% Black Results Black patients overall reported higher average ECOG scores and greater difficulty performing daily functions than White patients. PATIENTS REPORTING NOT BEING ABLE TO TAKE CARE OF THEMSELVES 0% Blacks 0% Whites Conclusion Significant racial disparities exist in performance status at an initial visit to an oncology clinic and, for Black patients, could mean: • Lower quality medical care pre-diagnosis • Poorer outcomes • Exclusion from clinical trials See Full Study The ERACE Patient Registry is foundational to its mission of eliminating inequities. The registry provides a real-world view of potential differences in clinical practice, patient outcomes, safety, and comparative effectiveness among cancer patients of color and other marginalized groups. Measurable Differences Among Minorities Learn more about ERACE Email* First name* Last name* Message I would like more information about:* ERACE ConcertAI Partnership Opportunities Advisory Board Membership Other ConcertAI is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you: I agree to receive other communications from ConcertAI. You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy. By clicking submit below, you consent to allow ConcertAI to store and process the personal information submitted above to provide you the content requested. Use Cases Commercial Solutions Study Design Regulatory Use External Control Arms AML Bladder Breast Gastric-Esophageal Lung Liver Melanoma Pancreatic Prostate Renal All Other Cancers Products & Services Data Products Predictive Patient STAR SPRINT Services Research Publications ERACE Resources Content Webinars and Events News Blog About Us Our Team Careers Investors Contact Us Request a Demo © 2017-2021 ConcertAI. All Rights Reserved. ConcertAI is a SymphonyAI company. Privacy Policy Terms of Use Privacy Policy Accept